Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25877960 | 0.77 | L3MBTL1 (0.41) | — | |
| SCHEMBL25877783 | 0.75 | ALDH1A1 (0.34) | — | |
| SCHEMBL24140923 | 0.72 | LATS1 (0.46) | LATS1LATS2 | |
| SCHEMBL24140918 | 0.72 | — | — | |
| SCHEMBL29679516 | 0.71 | EGFR (0.36) | EGFR | |
| SCHEMBL3133119 | 0.71 | EGFR (0.36) | EGFR | |
| SCHEMBL24141171 | 0.70 | KDM4E (0.46) | — | |
| SCHEMBL24141218 | 0.69 | LATS1 (0.46) | LATS1LATS2 | |
| SCHEMBL25877969 | 0.68 | CYP1A2 (0.38) | EGFRABL1 | |
| SCHEMBL31247673 | 0.68 | CHRNB2 (0.33) | LATS1LATS2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2021263079-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | LATS1 4429/4885LATS2 4576/4885EGFR 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.